Myriad Genetics focuses on advancing health through genetic testing, providing insights for hereditary cancer risk assessment, prenatal care, cancer management, and mental health treatment. The company self-describes its role in precision medicine.

Myriad Genetics

Myriad UroSuite™

Personalized Medicine & Companion Diagnostics

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. 

RainDance Technologies

Whether a woman has a personal or family history of cancer, genetic testing may help them uncover information that can help guide medical management decisions if they are at higher risk for cancer. Melissa Gonzales, President of Women's Health at Myriad, authored this Healthcare Business Today article on three genetic testing trends advancing women’s health in 2024. 

Here's a sneak peek:
📈 Bridging The Awareness Gap About Family Health History 
📈 New Research, Evolving Guidelines Drive Push For Genetic Testing
📈 Genetic Testing Fears Declining

Learn more: https://lnkd.in/gVESf_pK 

#genetictesting #womenshealth 

Join us for our January webinar in our Evolving Strategies in Genetics and Genomics 2024 continuing education webinar series. Our January webinar will highlight recent literature related to universal and germline testing in oncology genetics as well as unexpected findings in reproductive genetic screening with Alexandra Lisi and Flora Days.
 
Registration links are below: 
Tuesday, January 23rd, 2024 at 12:00PM ET
Registration Link: https://lnkd.in/esNM6uqz
Thursday, January 25th, 2024 at 3:00PM ET
Registration Link: https://lnkd.in/e87hzgPc
 
**This event has been approved by the National Society of Genetic Counselors (NSGC)  for Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification.  
  
**This nursing continuing professional development activity is pending approval for 1.25 contact hours from Oregon Nurses Association (ONA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation (ANCC).  Contact hours will be awarded to participants who attend the presentation and complete the post-activity survey. 
 
We look forward to having you join us this week! 


#continuingeducation #nurses #nursingeducation #geneticcounselor

Please join Myriad Genetics for our January webinar in our Evolving Strategies in Genetics and Genomics 2024 continuing education webinar series. Our January webinar will highlight recent literature related to universal and germline testing in oncology genetics as well as unexpected findings in reproductive genetic screening with Alexandra Lisi and Flora Days.
 
Registration links are below: 
Tuesday, January 23rd, 2024 at 12:00PM ET
Registration Link: https://lnkd.in/esNM6uqz
Thursday, January 25th, 2024 at 3:00PM ET
Registration Link: https://lnkd.in/e87hzgPc
 
**This event has been approved by the National Society of Genetic Counselors (NSGC)  for Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification.  
  
**This nursing continuing professional development activity is pending approval for 1.25 contact hours from Oregon Nurses Association (ONA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation (ANCC).  Contact hours will be awarded to participants who attend the presentation and complete the post-activity survey. 
 
We look forward to having you join us this week! 


#continuingeducation #nurses #nursingeducation #geneticcounselor
 

We're excited to announce that we have entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’ (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. Learn more: https://lnkd.in/edYjC4_V

“With this acquisition, we’re deepening our commitment to our oncology business while also generating a more effective way to scale and grow our tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities,” said Paul Diaz, president and CEO, Myriad Genetics. “We’d like to thank our longstanding partners at Intermountain Health for the important progress they’ve made in advancing precision oncology care. We look forward to continuing to build on this foundation to provide comprehensive genomic profiling options to the Intermountain Health System and its patients and providers that can help guide clinical care and improve patient outcomes.”

#oncology #genetictesting

What a year 2023 was - promoted to senior rep, team MVP & another President’s Club win. 

NSM in Tampa last week was great, loved getting to see so many friends and colleagues and to plan for a great 2024! ✨Grateful to work for Myriad Genetics and with my incredible manager & Mighty Mid team 🧬I love the work I’m able to do everyday - to directly impact the lives of many women (and men) through the testing Myriad provides. Here’s to 2024!

Service is love in action. It has the power to bring communities together, help others stand together against hate, build bridges, and heal divides. Service unites people regardless of race, ability, religion, or zip code. Now is the time to act on Dr. King’s “fierce urgency of now” and deliver on the promise of a Beloved Community. 

Remember, no act of kindness is too small. How are you serving your community today?

#MLKDay #BelovedCommunity #IServed

myRisk

Domain Not Resolving

DNSSEC

IPv6

Person Schema

Gravatar Profiles

CrUX Top 50m

Apple Mobile Web App Capable

ASP.NET

Amazon Virginia Region

SVP, Chief Compliance Officer

Clivetty Martinez, Ph.D, CCEP

Account Executive- Urologic Oncology ; Multi Year Presidents Club

Jef Reyburn

Legal

Jesse Oakeson

Chief Technology Officer

Kevin Haas

Associate General Counsel

Matthew Gordon

President, Women’s Health, Myriad Genetics

Melissa Gonzales

Pres., Chairman & CIO

Mike Whittington

SVP, Chief Accounting Officer

Natalie Munk

President

Nicole Lambert

Executive Vice President, Chief Legal Officer

Pamela Wong

Heiner Dreismann

Louise Phanstiel

Rashmi Kumar

Patrick Burke

EVP of Strategy and Innovation

Jerry Lanchbury

Sam Raha

Chief Operating Officer

Bryan Riggsbee

EVP Chief Financial Officer

Michelle Strecker

User Experience Designer III

Kevin Kimberlin

Co-Founder

Mark Skolnick

Jason Tang

Digital Project Manager

RainDance Technologies develops medical technology solutions.

Crescendo Bioscience develops diagnostic tools to provide rheumatologists with clinical insights to autoimmune and inflammatory disease.

Biotechnology Public Companies With More Than 500 Employees

Western US Companies With More Than $1M in Revenue (Top 10K)

United States Public Companies With More Than 10 Employees

Western US Public Companies With More Than $50M in Revenue

Myriad Genetics personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. 

Myriad is focused on three strategic imperatives:  maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.

Post-IPO Debt - Myriad Genetics

Medical and Beauty Services and Agricultural Services

Salt Lake City

Utah

United States

North America

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy

MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm

Driving Genetic Testing Adoption and Improved Patient Care through Health Data Intelligence

Pharmacogenomics Testing Buoys Myriad Genetics Q3 Revenues While Coverage Remains an Open Question

Myriad Genetics in Active Talks with UnitedHealthcare to Keep Coverage of GeneSight

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024

A genetic test that assesses the risk of developing 11 types of hereditary cancers, providing personalized risk assessments and management strategies.

A pharmacogenomic test that helps clinicians understand how a patient's genetics may affect their response to mental health medications.

A test for prostate cancer that evaluates the aggressiveness of the cancer to inform treatment decisions.

A comprehensive genomic profiling test for solid tumors, using next-generation sequencing to identify actionable genetic variants.

A genetic screening test for inherited conditions, helping prospective parents understand the risk of passing on genetic disorders.

A non-invasive prenatal test that screens for chromosomal conditions in a fetus as early as 10 weeks into pregnancy.

Kyrgyzstan

Asia

India

Germany

Europe

Canada

HTML5

Vimeo

Cloudflare CDN

F5 NGINX

Apache Server

Modernizr

jQuery

Office 365

Google Compute Engine

Bootstrap

Genomic Health is a competitor of Myriad Genetics in the genetic testing and precision medicine industry.

Genomic Health

BioFire Diagnostics competes with Myriad Genetics in the field of molecular diagnostics and infectious disease testing.

BioFire Diagnostics

Myriad Genetics is a leading genetic testing and precision medicine company based in Salt Lake City, Utah, United States. The company employs proprietary technologies to understand the genetic basis of human disease and its role in disease onset, progression, and treatment. Myriad provides genetic insights to empower individuals to take control of their health and enables healthcare providers to better detect, treat, and prevent disease.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

news impact assignment basic	general	Feb 15, 2024 3:09 PM	5cdfca84
public peers	general	Oct 2, 2024 2:09 PM	480ecc7e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 2, 2024 2:09 PM	c0c15a90
crunchbase trigger	general	Nov 25, 2024 9:06 AM	04dcc8a2
crunchbase profile	general	Nov 25, 2024 11:35 AM	7b1577ad
li profile	general	Feb 15, 2024 3:09 PM	d4b9cba1
translate crunchbase fundingrounds	general	Nov 25, 2024 2:14 PM	dbe358c6
peers	general	Oct 2, 2024 2:09 PM	9bee3d3c
news basic	general	Oct 2, 2024 2:09 PM	5bdc098d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:MYRIAD

Myriad Genetics

Last Close

15.12

22/11 21:00

Market Cap

2.28B

Beta: -

Volume Today

622.81K

Avg: -